A Theranostic Approach to Target Gastrin in Pancreatic Cancer

Banerjee, Sulagna; Saluja, Ashok K.

doi:10.1016/j.jcmgh.2018.04.002

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastrin tends to interact with the overexpressed cholecystokinin‐B (CCK‐B) receptor with a high affinity in various types of pancreatic cancer cells (Banerjee & Saluja, 2018). Therefore, different gastrin‐mediated delivery systems have been designed to target gastrin mRNA in pancreatic cancer cells.…”

Section: Nanoparticles‐based Delivery Systems For Pancreatic Cancer Sirna Therapymentioning

confidence: 99%

Nonviral siRNA delivery systems for pancreatic cancer therapy

Aghamiri

Raee

Talaei

et al. 2021

Biotech & Bioengineering

View full text Add to dashboard Cite

The serious drawbacks of the conventional treatment of pancreatic ductal adenocarcinoma (PDAC) such as nonspecific toxicity and high resistance to chemo and radiation therapy, have prompted the development and application of countless small interfering RNA (siRNA)‐based therapeutics. Recent advances in drug delivery systems hold great promise for improving siRNA‐based therapeutics and developing a new class of drugs, known as nano‐siRNA drugs. However, many fundamental questions, regarding toxicity, immunostimulation, and poor knowledge of nano‐bio interactions, need to be addressed before clinical translation. In this review, we provide recent achievements in the design and development of various nonviral delivery vehicles for pancreatic cancer therapy. More importantly, codelivery of conventional anticancer drugs with siRNA as a new revolutionary pancreatic cancer combinational therapy is completely discussed.

show abstract

Section: Nanoparticles‐based Delivery Systems For Pancreatic Cancer Sirna Therapymentioning

confidence: 99%

Nonviral siRNA delivery systems for pancreatic cancer therapy

Aghamiri

Raee

Talaei

et al. 2021

Biotech & Bioengineering

View full text Add to dashboard Cite

show abstract

“…Gastrin tends to interact with the overexpressed cholecystokinin-B (CCK-B) receptor with a high affinity in various types of pancreatic cancer cells (Banerjee & Saluja, 2018). Therefore, to target gastrin mRNA in pancreatic cancer cells, some researchers use gastrin-mediated delivery.…”

Section: Gastrinmentioning

confidence: 99%

Non-viral siRNA delivery systems for pancreatic cancer therapy

Aghamiri

Teymouri

Yeganeh

et al. 2020

Preprint

View full text Add to dashboard Cite

The serious drawbacks of conventional pancreatic ductal adenocarcinoma (PDAC) therapy like nonspecific toxicity and high resistance to chemo and radiation therapy, prompted the development and application of countless siRNA-based therapeutics. Significant technological success has been achieved in this area; however, the major challenges to siRNA-based therapeutics becoming a new paradigm in the pancreatic cancer therapy stem from enzymatic digestion, off-target effects, difficulty to enter cells, induction of innate immune responses, and renal clearance. Recent advances in drug delivery systems hold great promise for improving siRNA-based therapeutics and developing a new class of drugs, nano-siRNA drugs. However, a number of fundamental questions, regarding toxicity, immunostimulation, and poor knowledge of nano-bio interactions, need to be addressed before clinical translation. In this review, we provide recent achievements in designing and development of various non-viral delivery vehicles for pancreatic cancer therapy. More importantly, co-delivery of conventional anticancer drugs with siRNA as a new revolutionary pancreatic cancer combinational therapy is completely discussed.

show abstract

A Theranostic Approach to Target Gastrin in Pancreatic Cancer

Cited by 2 publications

References 12 publications

Nonviral siRNA delivery systems for pancreatic cancer therapy

Nonviral siRNA delivery systems for pancreatic cancer therapy

Non-viral siRNA delivery systems for pancreatic cancer therapy

Contact Info

Product

Resources

About